Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CG Oncology, Inc. Common stock (CGON)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/11/2025: CGON (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $60.33
1 Year Target Price $60.33
| 5 | Strong Buy |
| 4 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -38.6% | Avg. Invested days 19 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.98B USD | Price to earnings Ratio - | 1Y Target Price 60.33 |
Price to earnings Ratio - | 1Y Target Price 60.33 | ||
Volume (30-day avg) 10 | Beta - | 52 Weeks Range 14.80 - 40.47 | Updated Date 06/30/2025 |
52 Weeks Range 14.80 - 40.47 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.5 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -81161.54% |
Management Effectiveness
Return on Assets (TTM) -12.85% | Return on Equity (TTM) -16.58% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1290648742 | Price to Sales(TTM) 2987.99 |
Enterprise Value 1290648742 | Price to Sales(TTM) 2987.99 | ||
Enterprise Value to Revenue 1949.62 | Enterprise Value to EBITDA - | Shares Outstanding 76225296 | Shares Floating 61126599 |
Shares Outstanding 76225296 | Shares Floating 61126599 | ||
Percent Insiders 1.17 | Percent Institutions 105.34 |
Analyst Ratings
Rating 4 | Target Price 60.33 | Buy 4 | Strong Buy 5 |
Buy 4 | Strong Buy 5 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
CG Oncology, Inc. Common stock
Company Overview
History and Background
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing oncolytic immunotherapies for patients with bladder cancer. Founded in 2010, it has advanced its lead candidate, cretostimogene grenadenorepvec (Cretosto), through clinical trials.
Core Business Areas
- Oncolytic Immunotherapy Development: Developing Cretosto for the treatment of non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC).
Leadership and Structure
Arthur Kuan serves as the CEO. The company has a board of directors and a management team overseeing clinical development, regulatory affairs, and commercialization efforts.
Top Products and Market Share
Key Offerings
- Cretostimogene grenadenorepvec (Cretosto): An oncolytic immunotherapy being developed for NMIBC and MIBC. It is currently in late-stage clinical trials. Market share is currently 0, as the product is not yet approved for commercial use. Potential competitors include BCG therapy, Keytruda (pembrolizumab) for BCG-unresponsive NMIBC, and radical cystectomy.
Market Dynamics
Industry Overview
The oncology market is a large and growing market. Development of novel therapeutics and immunotherapies are in high demand. The bladder cancer treatment landscape includes surgical interventions, chemotherapy, radiation therapy, and immunotherapies.
Positioning
CG Oncology is focused on addressing unmet needs in bladder cancer treatment with Cretosto, which offers a novel mechanism of action as an oncolytic immunotherapy.
Total Addressable Market (TAM)
The global bladder cancer market is expected to reach billions of dollars. CG Oncology is positioned to capture a significant portion of the NMIBC and MIBC market with successful development and commercialization of Cretosto.
Upturn SWOT Analysis
Strengths
- Novel oncolytic immunotherapy approach
- Late-stage clinical development of Cretosto
- Experienced management team focused on bladder cancer
- Strong intellectual property position
Weaknesses
- Reliance on the success of Cretosto
- Lack of currently marketed products
- Potential regulatory hurdles
- Need for further funding to support clinical trials and commercialization
Opportunities
- Potential to address unmet needs in bladder cancer treatment
- Expansion of Cretosto to other cancer types
- Strategic partnerships with pharmaceutical companies
- Positive clinical trial results leading to regulatory approval
Threats
- Competition from existing and emerging bladder cancer therapies
- Clinical trial failures
- Regulatory delays or rejection
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- MRK (Merck & Co.)
- BMY (Bristol-Myers Squibb)
- AZN (AstraZeneca)
- IVAC (Immatics)
Competitive Landscape
CG Oncology's advantage lies in its novel oncolytic immunotherapy approach. It faces competition from established pharmaceutical companies with approved therapies for bladder cancer.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is based on the advancement of Cretosto through clinical trials.
Future Projections: Future growth depends on successful clinical trial outcomes, regulatory approvals, and commercialization of Cretosto. Analyst estimates are available from financial institutions.
Recent Initiatives: Focus on advancing Phase 3 trials for Cretosto in NMIBC and exploring potential applications in MIBC.
Summary
CG Oncology is a clinical-stage biopharmaceutical company focused on developing a novel immunotherapy for bladder cancer. The company's success hinges on the positive clinical results and regulatory approval of its lead drug candidate, Cretosto. While it operates in a competitive landscape, its novel approach offers a potential advantage. The company needs to manage its finances prudently to fund ongoing clinical trials and prepare for potential commercialization.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- ClinicalTrials.gov
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CG Oncology, Inc. Common stock
Exchange NASDAQ | Headquaters Irvine, CA, United States | ||
IPO Launch date 2024-01-25 | Chairman & CEO Mr. Arthur Kuan | ||
Sector Healthcare | Industry Biotechnology | Full time employees 113 | Website https://cgoncology.com |
Full time employees 113 | Website https://cgoncology.com | ||
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003, which is in phase 3 clinical trial for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 that is in phase 2 clinical trial to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy that is in phase 3 clinical trial for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008, which is in phase 2 clinical trial for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.